What is UgenTec?
Velsera, formerly known as UgenTec, is a specialized provider of automation solutions designed to optimize the complex workflows inherent in molecular laboratories. The company's flagship FastFinder platform provides a robust suite of tools that facilitate seamless integration between laboratory information systems and diagnostic instrumentation. By focusing on real-time quality control, automated sample flow, and actionable operational insights, Velsera addresses the critical need for reproducibility and efficiency in clinical, veterinary, and pharmaceutical diagnostics. The platform is engineered to reduce operational costs while ensuring that labs can maintain high standards of accuracy in an increasingly data-intensive diagnostic landscape.
How much funding has UgenTec raised?
UgenTec has raised a total of $13M across 3 funding rounds:
Private Equity
$1.4M
Angel/Seed
$2.3M
Series A
$9.3M
Private Equity (2015): $1.4M, investors not publicly disclosed
Angel/Seed (2016): $2.3M led by BNP Paribas Fortis
Series A (2018): $9.3M supported by Herman Verrelst, KU Leuven, Gemma Frisius Fund, Lrm, IMEC, and Annie Vereecken
Key Investors in UgenTec
Gemma Frisius Fund
The Gemma Frisius Fund is a seed capital fund associated with KU Leuven, one of Europe's oldest and most prestigious research universities, focusing on the commercialization of academic research.
LRM
LRM is a prominent venture capital provider that fosters economic development and innovation in the Limburg region by offering strategic financial support and managing business incubators.
BNP Paribas Fortis
BNP Paribas Fortis is a leading Belgian banking institution that provides comprehensive financial services and corporate banking solutions to support enterprise growth.
What's next for UgenTec?
With the support of its latest capital injection, Velsera is well-positioned to expand its footprint in the global diagnostics market. The strategic focus moving forward involves deepening the integration capabilities of the FastFinder platform to support a broader array of assay providers and instrument partners. As the demand for rapid, reliable molecular testing continues to rise, the company is expected to leverage its existing network of research and institutional partners to drive further innovation in laboratory automation. By prioritizing scalable software architecture, Velsera aims to set new benchmarks for diagnostic throughput and operational excellence in the life sciences sector.
See full UgenTec company page
